Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Condition:   Breast Neoplasms Intervention:   Drug: Endocrine therapy Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Introduction: Endocrine therapies (ETs) are associated with alopecia (EIA) in 15-25% of patients. There are no approved therapies for EIA. The purpose of this review is to provide dermatologists and oncologists with a foundation for the practical understanding of 5 α-reductase inhibitors and spironolactone for breast cancer patients and survivors with alopecia attributed to ETs, including the effect of these treatments on sex hormone levels, any reported drug interactions, and any risk of malignancy.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Background: Persistent hair disorders resulting from cytotoxic or endocrine agents used in early stages of breast cancer such as alopecia, hirsutism, and madarosis develop in 4-35% of patients, however their impact on quality of life (QoL) has not been reported. The CHANCE study is a prospective, longitudinal study of chemotherapy- and endocrine therapy-induced hair, skin, and nail changes in women with nonmetastatic breast cancer. This preliminary analysis intends to evaluate the impact of permanent hair sequelae of adjuvant breast cancer therapies on patients ’ QoL.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Breast cancers with positive expression of Estrogen Receptor (ER+) are treated with anti-hormone/endocrine therapy which targets the activity of the receptor, the half-life of the receptor or the availability of estrogen. This has significantly decreased mortality in women with ER+ breast cancer, however, about 25-30% of treated women run the risk or recurrence due to either intrinsic or acquired resistance to endocrine therapies. While ER itself is a predictor of response to such therapies, there exists a need to find more biomarkers and novel targets to treat resistant tumors. In this review, we summarize the known mecha...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
Conditions:   Estrogen Receptor-positive Breast Cancer;   Progesterone Receptor Positive Breast Cancer;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer A JCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer&...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We report clinical history of two patients with BRCA-mutated, ER-positive metastatic breast cancer treated with letrozole plus the CDK 4/6 inhibitor palbociclib. Biological and clinical implications of the treatment outcome observed in the two cases are discussed with the knowledge of scientific evidence to date available. Overall, biological rationale, preclinical and clinical data support the prominent role of CDK 4/6 inhibitors plus endocrine therapy, even in combination with PARP inhibitors, in the treatment of BRCA-mutated, ER-positive breast cancers. However, the interaction between Cyclin/CDK pathway, ER and BRCA i...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: We provide evidence that BETi either alone or in combination with FGFR1 inhibitors or BH3 mimetics may be a useful therapeutic strategy for recurrent ILC patients. PMID: 31409615 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Authors: Li Z, Chen Z, Hu G, Jiang Y Abstract Breast cancer is one of the most common cancers with the highest morbidity and mortality among women despite the treatment approaches have advanced including surgery, endocrine therapy and targeted therapy. Novel biomarkers are warranted to be discovered for the early detection, treatment and prognosis for breast cancer. CircRNA is a class of covalently closed single-stranded circular RNA molecules without free 5' or 3' end which makes them well expressed and more stable than their linear counterparts. In this review, we mainly discuss the oncogenic or anti-oncogenic ro...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
In conclusion, Denosumab administration can be considered effective and safe in the prevention and management of the above mentioned adverse events related to hormonal therapies designed for breast and prostate tumors.
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
Estrogen receptor positive breast tumors represent over 70% of diagnosed breast cancers. Depending on the stage at which the tumor is detected, HER2 status and genomic risk, endocrine therapy is combined with either radio, chemo and/or targeted therapy. A growing body of evidence supports the notion that components of the tumor microenvironment play specific roles in response to treatment and that strategies targeting these key interactions with tumor cells could pave the way to a new generation of therapies. In this review, we analyze the evidence supporting the role played by the different components of the tumor microen...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Hospitals | Research | Study